- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)

About This Event
Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.
Lusardi’s

George Alexopoulos, MD
DeWitt Wallace Distinguished Scholar, Founding Director, Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine

Jehan Marino, PharmD, BCPP
Medical Science Liaison

Erika Modh, PharmD, BCPS
Medical Science Liaison
Speaker George Alexopoulos, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speakers Jehan Marino, PharmD, BCPP and Erika Modh, PharmD, BCPS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Related Events
Registration
PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.